Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2018 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 700 | 366 | 659 |
| Marketable Securities | 2,088 | 493 | 601 |
| Receivables | 4,022 | 16 | 23 |
| Inventories | 1,176 | 8 | 15 |
| TOTAL | $7,986 | $883 | $1,298 |
| Non-Current Assets | |||
| PPE Net | 1,786 | 313 | 342 |
| Investments And Advances | 282 | 12 | 12 |
| Other Non-Current Assets | 63 | 24 | 0 |
| TOTAL | $2,130 | $349 | $354 |
| Total Assets | $10,115 | $1,231 | $1,652 |
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | 3,267 | 19 | 11 |
| TOTAL | $3,374 | $52 | $63 |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 42 | 12 | 0 |
| TOTAL | $80 | $57 | $67 |
| Total Liabilities | $3,453 | $109 | $130 |
| Shareholders' Equity | |||
| Shares Outstanding, K | 1,426 | 856 | N/A |
| Common Shares | 10,780 | 6,485 | 6,648 |
| Retained earnings | 761 | -333 | -87 |
| Other shareholders' equity | 134 | -17 | -27 |
| TOTAL | $6,662 | $1,122 | $1,522 |
| Total Liabilities And Equity | $10,115 | $1,231 | $1,652 |